» Articles » PMID: 30203710

The Molecular Imaging of Natural Killer Cells

Overview
Journal Mol Imaging
Publisher Sage Publications
Specialty Radiology
Date 2018 Sep 12
PMID 30203710
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The recent success of autologous T cell-based therapies in hematological malignancies has spurred interest in applying similar immunotherapy strategies to the treatment of solid tumors. Identified nearly 4 decades ago, natural killer (NK) cells represent an arguably better cell type for immunotherapy development. Natural killer cells are cytotoxic lymphocytes that mediate the direct killing of transformed cells with reduced or absent major histocompatibility complex (MHC) and are the effector cells in antibody-dependent cell-mediated cytotoxicity. Unlike T cells, they do not require human leukocyte antigen (HLA) matching allowing for the adoptive transfer of allogeneic NK cells in the clinic. The development of NK cell-based therapies for solid tumors is complicated by the presence of an immunosuppressive tumor microenvironment that can potentially disarm NK cells rendering them inactive. The molecular imaging of NK cells in vivo will be crucial for the development of new therapies allowing for the immediate assessment of therapeutic response and off-target effects. A number of groups have investigated methods for detecting NK cells by optical, nuclear, and magnetic resonance imaging. In this review, we will provide an overview of the advances made in imaging NK cells in both preclinical and clinical studies.

Citing Articles

Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.

Um-E-Kalsoom , Wang S, Qu J, Liu L Cancer Med. 2024; 13(19):e70155.

PMID: 39387259 PMC: 11465031. DOI: 10.1002/cam4.70155.


ImmunoPET provides a novel way to visualize the CD103 tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Fan X, Nijman H, de Bruyn M, Elsinga P EJNMMI Res. 2024; 14(1):5.

PMID: 38182929 PMC: 10769965. DOI: 10.1186/s13550-023-01062-6.


Advances in NK cell therapy for brain tumors.

Fares J, Davis Z, Rechberger J, Toll S, Schwartz J, Daniels D NPJ Precis Oncol. 2023; 7(1):17.

PMID: 36792722 PMC: 9932101. DOI: 10.1038/s41698-023-00356-1.


Emerging applications of nanotechnology in context to immunology: A comprehensive review.

Mobeen H, Safdar M, Fatima A, Afzal S, Zaman H, Mehdi Z Front Bioeng Biotechnol. 2023; 10:1024871.

PMID: 36619389 PMC: 9815620. DOI: 10.3389/fbioe.2022.1024871.


Nanomaterials for Natural Killer Cell-Based Immunoimaging and Immunotherapies in Cancer.

Uthaman S, Cutshaw G, Ghazvini S, Bardhan R ACS Appl Mater Interfaces. 2022; .

PMID: 36006784 PMC: 10176446. DOI: 10.1021/acsami.2c08619.


References
1.
Wang Q, Liu F, Liu L . Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore). 2017; 96(18):e6369. PMC: 5419898. DOI: 10.1097/MD.0000000000006369. View

2.
Campbell K, Hasegawa J . Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013; 132(3):536-544. PMC: 3775709. DOI: 10.1016/j.jaci.2013.07.006. View

3.
Vivier E, Ugolini S . Natural killer cells: from basic research to treatments. Front Immunol. 2012; 2:18. PMC: 3342003. DOI: 10.3389/fimmu.2011.00018. View

4.
Davis Z, Felices M, Verneris M, Miller J . Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015; 21(6):486-91. PMC: 4763946. DOI: 10.1097/PPO.0000000000000156. View

5.
Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P . Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 2016; 76(8):2153-65. DOI: 10.1158/0008-5472.CAN-15-1965. View